Drug interactions between Lipitor and Trilipix
| Results for the following 2 drugs: |
|---|
| Lipitor (atorvastatin) |
| Trilipix (fenofibric acid) |
Interactions between your selected drugs
atorvastatin ↔ fenofibric acid
Applies to:Lipitor (atorvastatin) and Trilipix (fenofibric acid)
MONITOR CLOSELY: Data from observational studies suggest that the risk of severe myopathy and rhabdomyolysis is increased when fibric acid derivatives are coadministered with an HMG-CoA reductase inhibitor (i.e., statin), even in the absence of a marked pharmacokinetic interaction. Additive pharmacodynamic effects may be involved, since these agents individually have been associated with the development of myopathy. Although gemfibrozil has been implicated most often, presumably due to a pharmacokinetic interaction with statins that significantly increases their concentrations in plasma, other fibrates have also been involved. In clinical trials for delayed-release fenofibric acid, myalgia was reported in 3.3% of patients receiving monotherapy and 3.1% to 3.5% of patients receiving concomitant statin therapy, compared to 4.7% to 6.1% of patients receiving statin monotherapy. Increases in creatine phosphokinase (CPK) to greater than 5 times upper limit of normal occurred in no patients receiving fenofibric acid monotherapy and 0.2% to 1.2% of patients receiving concomitant statin therapy, compared to 0.4% to 1.3% of patients receiving statin monotherapy. Addition of a fibrate to HMG-CoA reductase inhibitor therapy typically provides little additional reduction in LDL cholesterol, but further reductions of triglycerides and increases in HDL cholesterol may be attained.
MANAGEMENT: Caution is advised if delayed-release fenofibric acid is coadministered with a statin. A lower dosage of the statin may be appropriate, particularly if the patient is already receiving the maximum dosage. Coadministration with the maximum dosage of a statin has not been evaluated in clinical studies and should be avoided unless the benefits are expected to outweigh the risks. All patients treated with HMG-CoA reductase inhibitors and/or fibrates should be advised to promptly report any unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Therapy should be discontinued if creatine kinase is markedly elevated in the absence of strenuous exercise or if myopathy is otherwise suspected or diagnosed. In addition, patients should be closely monitored for hepatotoxicity.
See also...
Drug Interaction Classification
The classifications below are a guideline only. The relevance of a particular drug interaction to a specific patient is difficult to determine using this tool alone given the large number of variables that may apply.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
